Number Needed to Treat in Multiple Sclerosis Clinical Trials Macaulay OkwuokenyeAnnie ZhangKarl E. Peace Review Open access 07 February 2017 Pages: 1 - 9
Informal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer’s Disease: Determinants and Level of Change Observed Loretto LaceyJoel BobulaChristopher Leibman Original Research Open access 22 November 2016 Pages: 11 - 23
Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study Kimiko KadoharaIzumi SatoKoji Kawakami Original Research Open access 28 November 2016 Pages: 25 - 37
Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial Takahiko SaidaJun-Ichi Kiraon behalf of the Natalizumab Trial Principal Investigators Original Research Open access 05 December 2016 Pages: 39 - 55
Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study Michael DennisLaura ShineSinead Brophy Original Research Open access 04 January 2017 Pages: 57 - 77
Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients Andrew LeeJames PikeEddie Jones Original Research Open access 16 January 2017 Pages: 79 - 90
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database Aaron BosterJacqueline NicholasAndrew Lee Original Research Open access 16 February 2017 Pages: 91 - 102
Depression Among HIV/AIDS Patients on Highly Active Antiretroviral Therapy in the Southwest Regional Hospitals of Cameroon: A Cross-Sectional Study Pleasure Atoh NgumPeter Nde FonHenri Namme Luma Original Research Open access 18 March 2017 Pages: 103 - 114
Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort Study Vanja SikiricaPer A. GustafssonCharles Makin Original Research Open access 28 April 2017 Pages: 115 - 130
A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients Nawal Bent-EnnakhilFlorence CosteHoward Fillit Original Research Open access 15 May 2017 Pages: 131 - 144
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study Simona MalucchiMarco CapobiancoAntonio Bertolotto Brief Report Open access 03 December 2016 Pages: 145 - 152
Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis Takahiko SaidaJun-Ichi KiraJ. T. Tibung Brief Report Open access 11 January 2017 Pages: 153 - 159